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Spinal muscular atrophy (SMA) is a motor neuron disease caused by reduced levels of the survival motor neuron (SMN) protein.
SMN together with Gemins2-8 and unrip proteins form a macromolecular complex that functions in the assembly of small
nuclear ribonucleoproteins (snRNPs) of both the major and the minor splicing pathways. It is not known whether the levels of
spliceosomal snRNPs are decreased in SMA. Here we analyzed the consequence of SMN deficiency on snRNP metabolism in the
spinal cord of mouse models of SMA with differing phenotypic severities. We demonstrate that the expression of a subset of
Gemin proteins and snRNP assembly activity are dramatically reduced in the spinal cord of severe SMA mice. Comparative
analysis of different tissues highlights a similar decrease in SMN levels and a strong impairment of snRNP assembly in tissues
of severe SMA mice, although the defect appears smaller in kidney than in neural tissue. We further show that the extent of
reduction in both Gemin proteins expression and snRNP assembly activity in the spinal cord of SMA mice correlates with
disease severity. Remarkably, defective SMN complex function in snRNP assembly causes a significant decrease in the levels of
a subset of snRNPs and preferentially affects the accumulation of U11 snRNP—a component of the minor spliceosome—in
tissues of severe SMA mice. Thus, impairment of a ubiquitous function of SMN changes the snRNP profile of SMA tissues by
unevenly altering the normal proportion of endogenous snRNPs. These findings are consistent with the hypothesis that SMN
deficiency affects the splicing machinery and in particular the minor splicing pathway of a rare class of introns in SMA.
Citation: Gabanella F, Butchbach MER, Saieva L, Carissimi C, Burghes AHM, et al (2007) Ribonucleoprotein Assembly Defects Correlate with Spinal
Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs. PLoS ONE 2(9): e921. doi:10.1371/journal.pone.0000921
INTRODUCTION
Spinal muscular atrophy (SMA) is an autosomal recessive disorder
characterized by degeneration of motor neurons in the spinal cord
and skeletal muscle atrophy. SMA is the leading genetic cause of
death in infancy and is classified into three types based on the age
of onset and clinical severity [1–5]. Type I is the most severe and
frequent form of SMA with disease onset before six months of age
and death usually by the age of two. Type II is the intermediate
form with onset prior to eighteen months and patients never
gaining the ability to walk. Type III is the mild form characterized
by onset after eighteen months with the ability to walk and
a normal life expectancy. Very severe fetal-onset (type 0) and very
mild adult-onset (type IV) forms of SMA have also been described.
Irrespective of disease severity, all SMA patients have homozygous
deletionsormutationsinthesurvivalmotorneuron(SMN1)gene,the
SMA-determining gene, and retain at least one copy of the nearly
identical SMN2 gene [6]. A single nucleotide difference functionally
distinguishes SMN1 from SMN2, affecting the amount of exon 7
inclusionintheSMNtranscript [7,8].Thelossofexon7removesthe
carboxy-terminal amino acids making SMND7 protein unstable and
rapidly degraded [9]. As a consequence, the SMN2 gene produces
low levels of full-length SMN and cannot compensate for the loss of
SMN1 in SMA. However, the SMN2 gene copy number acts as
a modifierofdiseaseseverity[10],which inverselycorrelateswith the
levels of SMN expression in patients [11,12].
The SMN gene is ubiquitously expressed and is essential for
viability in many organisms from yeast to humans. To understand
SMA etiology and support therapeutics development, a number of
different animal models of SMA have been created and SMA mice
more closely resemble the feature of SMA pathology in humans
[3,13]. Distinct strategies have been employed to circumvent the
early embryonic lethality associated with the knockout of the single
Smn gene in mice and generate mouse models of SMA [14–17].
Similar to the situation in the human disease, expression of the
human SMN2 gene in the mouse Smn null background rescues
embryonic lethality and results in mice with SMA [15,16].
Importantly, the severity of the phenotype is dependent on the
SMN2 copy number. Severe SMA mice with a single SMN2 gene
die embryonically while mice with two SMN2 copies survive on
average for five days [15,16]. These mice have reduced weight and
severe motor impairment before appreciable loss of motor neuron
cell bodies, which occurs at postnatal day 3. Eight or more SMN2
gene copies fully rescue the SMA phenotype in SMA mice [16].
Interestingly, introducing a SMND7 transgene that encodes
a SMN isoform lacking exon 7–which is the predominant isoform
produced by the SMN2 gene–to a severe SMA mouse genetic
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SMND7 SMA mice still display a considerably severe phenotype
and die on average at two weeks of age. A mouse model of the
mild form of SMA was generated by introducing SMN(A2G),
a SMN point mutant found in type III SMA patients, to the severe
SMA background [19]. SMN(A2G) SMA mice display very late
onset of muscle weakness and motor impairment, moderate loss of
motor neurons, and survive over one year. Collectively, these
studies indicate that reduced SMN activity causes SMA and that
disease severity inversely correlates with SMN levels in both
human patients and mouse models.
The molecular defect responsible for motor neuron degenera-
tion in SMA is unknown. SMN is a multifunctional protein that
has been implicated in a variety of cellular processes, many of
which are linked to RNA metabolism [20,21]. It is well established
that SMN associates with itself and at least eight additional
proteins (Gemins2-8 and unrip) to form a macromolecular
complex referred to as the SMN complex [22]. To date, the only
molecularly defined cellular activity of the SMN complex is its
function in the biogenesis of small nuclear ribonucleoproteins
(snRNPs), the essential components of the pre-mRNA splicing
machinery that catalyze the excision of introns from mRNA
precursors in the nucleus. Spliceosomal snRNPs of the Sm class
comprise an snRNA molecule (U1, U2, U4, U4atac, U5, U11 and
U12), seven common Sm proteins and additional proteins specific
for each snRNP [23]. The snRNP biogenesis pathway requires the
activity of a number of auxiliary factors and takes place in both the
nucleus and the cytoplasm [22,23]. In the cytoplasm, the SMN
complex mediates the ATP-dependent assembly of a heptameric
ring of Sm proteins around a conserved sequence of the snRNAs
to form the Sm core [24–26]. Consistent with the essential role for
the SMN complex in snRNP assembly, reducing expression of
either SMN or Gemin proteins in cultured cells affects Sm core
formation [27–33]. It is, however, becoming increasingly clear that
SMN may have additional functions in distinct cell types that are
unrelated to snRNP biogenesis and are relevant to SMA [34–37].
A subset of SMN complexes that do not contain Sm proteins
traffic into axons and growth cones of motor neurons and may be
involved in some aspects of the axonal transport and localized
translation of specific mRNAs [38,39]. Accordingly, cultured
primary motor neurons from severe SMA mice display reduced
accumulation of b-actin mRNA in growth cones and defective
axon outgrowth [37].
One of the most pressing issues in SMA biology is whether
deficiencies in snRNP biogenesis, axonal SMN function(s) or
possibly even both are responsible for motor neuron degeneration
in SMA. A link between deficiencies in snRNP biogenesis and
SMA pathology is suggested by the observation that some SMN
mutants of SMA patients display defective binding to Sm proteins
and snRNP assembly activity in vitro [31,40,41]. Moreover,
extracts from human fibroblast and lymphoblast cell lines of type
I SMA patients have reduced snRNP assembly activity compared
with normal controls [32]. To date, the most direct evidence that
defects of snRNP metabolism may trigger motor neuron de-
generation in SMA is that injection of snRNPs rescues motor axon
outgrowth and pathfinding defects caused by knockdown of SMN
in zebrafish embryos [33,35]. Although in the zebrafish model
system is important to distinguish whether motor axon defects are
cell autonomous or secondary to general development defects
which cause axonal abnormalities [34,35], knockdown of two
additional factors involved in the pathway of snRNP biogenesis
reportedly also affects motor axon outgrowth [33]. These findings,
together with the observation that SMN activity in snRNP
assembly is very prominent during embryonic and early postnatal
development but is strongly down regulated after myelination in
the mouse spinal cord [42], suggest that developmental deficien-
cies in snRNP biogenesis may underlie motor neuron degenera-
tion in SMA. According to this view, reduced SMN activity in
snRNP assembly would affect the accumulation of snRNPs
thereby weakening the splicing machinery. To date, however,
there has been no evidence that snRNP levels are affected in SMA.
Furthermore, endogenous snRNP levels are not decreased in
chicken DT40 cells with markedly reduced SMN levels and
impaired Sm core formation as well as in Drosophila larvae that
harbor lethal SMN null mutations [32,36]. These observations
raise the issue as to whether snRNP assembly activity in SMA ever
falls significantly below the threshold that would affect the steady-
state snRNP levels in vivo [22]. Here, we sought to address the
consequencesofSMNdeficiencyonsnRNPmetabolisminthespinal
cord, the target tissue of SMA.To do so, we analyzed SMN complex
expression, Sm core formation activity and endogenous snRNP
levels in tissues of mouse models of SMA. Our results indicate that
disease severity correlates with the degree of impairment of SMN
complex expression and snRNP assembly activity in the spinal cord
of SMA mice. Remarkably, defective SMN complex function in
snRNPassemblycauses a significant decreaseinthe levels of a subset
of spliceosomal snRNPs and preferentially affects the accumulation
of U11 snRNP of the minor splicing pathway in tissues from severe
SMA mice. Thus, SMN deficiency unevenly alters the physiological
proportion of endogenous snRNPs in SMA.
RESULTS
SMN complex expression in the spinal cord of severe
SMA mice
To analyze the expression of the integral components of the SMN
complex in the spinal cord of severe SMA mice, we isolated spinal
cords from normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;mSmn
+/
2) and severe SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day 3.
Total proteins from these tissues were analyzed by Western blot
with antibodies against SMN complex components and several
SMN-interacting proteins (Figure 1). Similar levels of tubulin and
core histones indicate that equal amounts of proteins were present.
Compared with normal controls, the levels of Gemin2, Gemin6
and Gemin8 are strongly decreased in the spinal cord of severe
SMA mice that express low levels of SMN. Interestingly, Gemin8
is the SMN complex component whose expression is most affected
by reduced levels SMN. In contrast, there is little if any reduction in
the expression of Gemin4 and unrip proteins, two other integral
components of the SMN complex. Although we did not analyze the
levels of Gemin3, Gemin5 and Gemin7 for lack of suitable
antibodies, decreasing SMN expression in HeLa cells by RNA
interference to an extent similar to that in the spinal cord of SMA
mice significantly reduces the levels of Gemin2, Gemin6, Gemin7
and Gemin8 but not of Gemin3, Gemin4, Gemin5 or unrip proteins
(Figure S1). Interestingly, the levels of several SMN-interacting
proteinssuchasSmB,hnRNPR,hnRNPQ,profilinIandprofilinII
are not decreased in the spinal cord of severe SMA mice.
Collectively, these results demonstrate that reduced levels of SMN
markedly affect the expression of a subset of Gemin proteins and in
particular of Gemin8 in the spinal cord of severe SMA mice.
SMN levels and snRNP assembly defects in tissues of
severe SMA mice
The best-characterized function of the SMN complex is in the
assembly of the Sm core on spliceosomal snRNAs [22,23]. To
analyze the effect of reduced SMN expression on snRNP assembly
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kidneys from normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;
mSmn
+/2) and severe SMA (SMN2
+/+;mSmn
2/2) mice at postnatal
day 3. For each genotype, Western blot analyses show that these
tissues contain similar levels of SMN when normalized per cell
number (Figure 2A). This pattern is also observed when equal
amounts of whole tissue extracts are compared (Figure 2B). To
evaluate the extent of SMN decrease, we compared the intensity of
SMN signals detected by western blot in serial dilutions of whole
spinal cord extracts from normal, carrier and severe SMA mice.
SMN levels in spinal cord extracts from carrier and severe SMA
mice are, respectively, two-fold and eight-fold lower than in
normal mice (Figure 2C). We then analyzed the capacity of equal
amounts of these tissue extracts to form Sm cores on in vitro
transcribed radioactive U1 snRNA using a well-established ATP-
dependent snRNP assembly assay and both gel shift and
immunoprecipitation with anti-Sm antibodies [26,42]. Spinal cord
and brain extracts from normal and carrier mice display very
efficient snRNP assembly, which is dramatically impaired in the
corresponding extracts of severe SMA mice (Figure 3A and 3B).
Despite similar amounts of SMN (Figure 2B), kidney extracts from
normal and carrier mice show very low Sm core formation
compared with extracts from the CNS (Figure 3B) and the
Figure 2. Analysis of SMN levels in different tissues of severe SMA
mice. (A) Western blot analysis of total proteins from spinal cord, brain
or kidney of normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;mSmn
+/2) and
severe SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day 3. Extracts
normalized per cell number (equal amounts of core histones) were
analyzed by SDS/PAGE and Western blot with antibodies against the
proteins indicated on the left. (B) Western blot analysis of equal
amounts of whole tissue extracts (25 mg) from spinal cord, brain or
kidney of normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;mSmn
+/2) and
severe SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day 3. Proteins were
analyzed by SDS/PAGE and Western blot with antibodies against SMN
and tubulin. (C) Analysis of SMN decrease in the spinal cord of severe
SMA mice. Western blot analysis of the indicated serial dilutions (100
equals 50 mg of proteins) of whole tissue extracts from the spinal cord
of normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;mSmn
+/2) and severe
SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day 3. Proteins were
analyzed by SDS/PAGE and Western blot with antibodies against SMN
and tubulin.
doi:10.1371/journal.pone.0000921.g002
Figure 1. Expression of SMN complex components in the spinal cord
of severe SMA mice. Western blot analysis of equal amounts of total
proteins from the spinal cord of normal (SMN2
+/+;mSmn
+/+), carrier
(SMN2
+/+;mSmn
+/2) and severe SMA (SMN2
+/+;mSmn
2/2)m i c ea t
postnatal day 3. All mice harbored two copies of human SMN2 gene
together with two, one or no copies of the mouse mSmn gene. Proteins
were analyzed by SDS/PAGE and Western blot with antibodies against
the proteins indicated on the left.
doi:10.1371/journal.pone.0000921.g001
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detected upon longer exposure of immunoprecipitation experi-
ments (Figure S2). We have shown previously that snRNP
assembly is much more prominent in the CNS than in other
mouse tissues during embryogenesis and early postnatal de-
velopment likely because of changes in the SMN complex activity
that occur during development and cellular differentiation [42].
Developmental down-regulation of Sm core formation has been
reportedly observed also in Drosophila extracts [36]. Thus,
differences in the snRNP assembly activity of distinct tissues from
normal mice are consistent with these studies. To quantify the
snRNP assembly defect in SMA tissues, the levels of immunopre-
cipitated U1 snRNA were calculated from four independent
experiments in which all tissue extracts were prepared and
analyzed at the same time as in Figure 3B to minimize variations.
Values are presented following normalization either inter-tissue
(Figure 3C) or intra-tissue (Figure 3D). The snRNP assembly
activity is decreased ten-fold in both spinal cord and brain extracts
from severe SMA mice compared with normal mice (p,0.0001)
and approximately four-fold in kidney extracts from severe SMA
Figure 3. In vitro snRNP assembly activity in tissues of severe SMA mice. (A) Equal amounts of whole tissue extracts (25 mg) from spinal cord, brain
or kidney of normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;mSmn
+/2) and severe SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day 3 were analyzed in
snRNP assembly reactions with radioactive U1 snRNA followed by electrophoresis on native polyacrylamide gels. The position of U1 RNP complexes
containing the Sm core is indicated on the left. (B) In vitro snRNP assembly reactions as in (A) were analyzed by immunoprecipitation with anti-Sm
(Y12) antibodies followed by electrophoresis on denaturing polyacrylamide gels and autoradiography. (C) Quantification of snRNP assembly activity
in whole tissue extracts from normal, carrier and SMA mice. The amount of U1 snRNA immunoprecipitated in snRNP assembly experiments as in (B)
was quantified using a STORM 860 Phosphorimager (Molecular Dynamics) and expressed as a percentage of that in brain extracts of normal mice,
which is set arbitrarily as 100%. The values from four independent experiments are presented as mean6SEM (*p,0.0001, **p,0.05). (D) For each
tissue, the amount of U1 snRNA immunoprecipitated in snRNP assembly experiments with extracts from carrier (SMN2
+/+;mSmn
+/2) and SMA (SMN2
+/
+;mSmn
2/2) mice is expressed as a percentage of that in the corresponding extract from normal (SMN2
+/+;mSmn
+/+) mice, which is set arbitrarily as
100%.
doi:10.1371/journal.pone.0000921.g003
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snRNP assembly is only marginally reduced in spinal cord extracts
from carrier mice that have approximately half the amount of
SMN of normal mice (p.0.05, not significant). Altogether these
results show a similar reduction in SMN levels and a strong
impairment of snRNP assembly activity in tissues of severe SMA
mice, although the defect appears smaller in kidney than in neural
tissue.
snRNP assembly defects in the spinal cord of SMA
mice correlate with disease severity
To investigate a potential correlation between impaired snRNP
assembly and SMA severity, we analyzed SMN complex
expression and snRNP assembly activity in the spinal cord of
different mouse models of SMA, including SMND7 SMA mice,
mild SMN(A2G) SMA mice and phenotypically rescued high copy
SMN2 SMA mice. Figure 4A shows Western blot analysis of SMN
complex expression in whole spinal cord extracts from normal
(SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;mSmn
+/2), severe SMA
(SMN2
+/+;mSmn
2/2), SMND7 SMA (SMN2
+/+;SMND7
+/+;
mSmn
2/2), SMN(A2G) SMA (SMN2
+/+;SMN(A2G)
+/2;
mSmn
2/2) and high copy SMN2 SMA (SMN2
+/2;
SMN2(566)
+/2;mSmn
2/2) mice at postnatal day 3. The levels
of Gemin2, Gemin6 and Gemin8 are strongly decreased in both
severe SMA and SMND7 SMA mice compared with normal and
carrier mice (Figure 4A). Remarkably, expression of these Gemin
proteins is partially restored in the spinal cord of mild SMN(A2G)
SMA mice and equivalent to that of controls in the spinal cord of
high copy SMN2 SMA mice, which is consistent with the complete
rescue of the SMA phenotype. These results highlight a strong
correlation between disease severity and decreased expression of
Gemin proteins in the spinal cord of SMA mice.
Next, we investigated snRNP assembly activity in spinal cord
extracts from the same mice at postnatal day 3. The efficiency of
Sm core formation was analyzed by immunoprecipitation of U1
snRNA from snRNP assembly reactions using anti-Sm antibodies
and representative results are shown in Figure 4B. Quantification
of U1 levels indicates that there is a ten-fold decrease (p,0.0001)
in the snRNP assembly activity of spinal cord extracts from both
severe SMA and SMND7 SMA mice compared with normal
controls (Figure 4C). Importantly, intermediate levels of snRNP
assembly activity are found in SMN(A2G) SMA mice, which are
approximately three- to four-fold higher than in severe SMA mice
(p,0.05) and two-fold lower than in normal controls (p,0.0001).
The snRNP assembly activity in spinal cord extracts from normal,
Figure 4. In vitro snRNP assembly defects correlate with SMA
severity. (A) Western blot analysis of equal amounts of whole tissue
extracts (25 mg) from the spinal cord of normal (SMN2
+/+;mSmn
+/+),
carrier (SMN2
+/+;mSmn
+/2), severe SMA (SMN2
+/+;mSmn
2/2), SMND7
r
SMA (SMN2
+/+;SMND7
+/+;mSmn
2/2), SMN(A2G) SMA (SMN2
+/
+;SMN(A2G)
+/2 ;mSmn
2/2) and high copy SMN2 SMA (SMN2
+/
2;SMN2(566)
+/2;mSmn
2/2) mice at postnatal day 3. Proteins were
analyzed by SDS/PAGE and Western blot with antibodies against the
proteins indicated on the left. (B) Representative snRNP assembly
reactions carried out using in vitro transcribed radioactive U1 snRNA
and 25 mg of whole spinal cord extracts as in (A) followed by
immunoprecipitation with anti-Sm (Y12) antibodies. Immunoprecipi-
tated U1 snRNAs were analyzed by electrophoresis on denaturing
polyacrylamide gels and autoradiography. (C) Quantification of snRNP
assembly activity in spinal cord extracts from control and SMA mice of
different severity. Spinal cord extracts from at least five mice for each of
the indicated genotypes were analyzed by snRNP assembly and
immunoprecipitation experiments as in (B). The amount of immuno-
precipitated U1 snRNA was quantified using a STORM 860 Phosphor-
imager (Molecular Dynamics). The values are presented as mean6SEM.
SMN2 high refers to SMN2(566).
doi:10.1371/journal.pone.0000921.g004
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different (p.0.05). This is particularly interesting in the case of
carrier mice (SMN2
+/+;mSmn
+/2) in which an approximately 50%
reduction of SMN levels has very modest if any effects on snRNP
assembly activity. Altogether these findings demonstrate that
disease severity correlates with the degree of impairment of the
SMN complex activity in snRNP assembly in the spinal cord of
SMA mice.
snRNP biogenesis is not affected in human
fibroblasts from SMA type I patients
Next, we sought to investigate whether reduced SMN levels and
snRNP assembly activity resulted in decreased levels of newly
assembled snRNPs in SMA cells. To do so, we used well-
characterized human fibroblasts cell lines from type I SMA
patients. Western blot analysis shows a reduction in SMN levels
ranging from 50% to 75% in four different human SMA fibroblast
cell lines compared with control fibroblasts from an healthy carrier
individual (Figure 5A). Also, snRNP assembly activity in whole
extracts from these human SMA fibroblasts is reduced approxi-
mately two- to three-fold (data not shown), which is proportional
to the decrease in SMN levels and in agreement with the results of
a previous study that analyzed Sm core formation in the same cell
lines [32]. To study the consequence of this biochemical deficiency
on snRNP synthesis in vivo, control and type I SMA fibroblasts
were grown in the presence of [
32P] phosphoric acid for six hours
to label newly synthesized snRNPs, which were then isolated by
immunoprecipitation with anti-Sm antibodies from equal amounts
of cell extracts. Surprisingly, we found no significant difference in
the levels of snRNPs that are synthesized in control and type I
SMA fibroblasts (Figure 5B). Consistent with this, steady-state
snRNP levels are also unchanged in these cells (data not shown).
Under similar experimental conditions, inihibition of snRNP
biogenesis with leptomycin B—a compound that blocks snRNA
export from the nucleus [43]—causes a dramatic decrease in the
amount of newly synthesized snRNPs indicating that the
immunoprecipitation assay is not saturated (data not shown).
These results demonstrate that, despite a two- to three-fold
reduction in both SMN levels and snRNP assembly activity,
snRNP biogenesis is not affected in human type I SMA fibroblasts
because fibroblasts contain an excess capacity for Sm core formation
relative to their actual requirement for snRNP synthesis in vivo.
The levels of a subset of snRNPs are reduced in
tissues of severe SMA mice
Monitoring snRNP synthesis in mouse tissues with pulse-labeling
experiments such as those described above is not feasible. To
address the in vivo consequence of SMN deficiency on snRNP
metabolism in the spinal cord of severe SMA mice, we analyzed
the steady-state levels of endogenous snRNPs. To do so, we
carried out immunoprecipitation experiments with anti-Sm
antibodies from equal amounts of whole spinal cord extracts from
normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;mSmn
+/2) and
severe SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day 3.
Immunoprecipitated snRNAs were then labeled at the 39-end
with [
32P] pCp and analyzed by electrophoresis on denaturing gels
and autoradiography, thereby allowing simultaneous assessment of
Sm core-containing snRNAs. Figure 6 shows that the levels of at
least some snRNPs are decreased in spinal cord extracts from
severe SMA mice compared with normal controls. Despite
a general trend towards reduction, quantification of snRNA levels
from four independent experiments highlights a statistically
significant decrease (p,0.05) in the levels of U1, U2, U11 and
U12 but not of U4 or U5 snRNAs in the spinal cord of severe
SMA mice when compared with carrier mice (Figure 7). Remark-
ably, U11 is the most severely affected with an average 60%
reduction (p=0.018). These findings were further confirmed by
Northern blot analysis of U1 and U11 snRNA levels, which are
reduced by 15% and 30% in the spinal cord of severe SMA mice,
respectively (Figure 8). Northern blot analysis of total snRNA
levels does not distinguish between snRNAs that contain the Sm
core and those that do not, and the snRNA decrease is smaller
than measured with immunoprecipitation experiments. This
observation raises the possibility that a significant fraction of
snRNAs is not associated with Sm proteins in SMA tissues. Similar
Figure 5. SMN levels and in vivo snRNP synthesis in human
fibroblasts from type I SMA patients. (A) SMN levels in type I SMA
fibroblast cell lines. Western blot analysis of equal amounts of whole
cell extracts (25 mg) from human fibroblast cell lines of a normal
individual (GM03814) and four type I SMA patients (GM00232,
GM09677, GM03813 and GM03815). Proteins were analyzed by SDS/
PAGE and Western blot with antibodies against SMN and tubulin. (B) In
vivo snRNP synthesis in type I SMA fibroblast cell lines. The human
fibroblast cell lines in (A) were pulse-labeled in vivo for 6 h with [
32P]
phosphoric acid and equal amounts of extracts from these cells
(200 mg) were then immunoprecipitated with anti-Sm (Y12) antibodies.
The immunoprecipitated snRNAs were analyzed by electrophoresis on
denaturing polyacrylamide gels and autoradiography. Known snRNAs
are indicated on the left.
doi:10.1371/journal.pone.0000921.g005
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same mice. Interestingly, the consequence of low SMN expression
in these tissues differs from the spinal cord because only the levels
of U11 and U12 snRNPs in brain and of U11 snRNP in kidney
are significantly reduced in severe SMA mice compared with
carrier mice (Figure 7). Collectively, these results show that the
levels of a subset of snRNPs are reduced in tissues from severe
SMA mice, and that defective SMN complex activity in snRNP
assembly preferentially affects the accumulation of U11 snRNP of
the minor splicing pathway in vivo. Thus, SMN deficiency unevenly
changes the snRNP profile of SMA tissues.
DISCUSSION
Despite steady progress in our understanding of the genetic basis
of SMA, the molecular functions of SMN and the development of
animal models, the defect responsible for the specific degeneration
of motor neurons in the spinal cord of SMA patients remains
elusive. The best-characterized activity of the SMN complex is the
assembly of Sm proteins onto snRNAs forming the spliceosomal
snRNPs [20–23]. These abundant nuclear RNPs function in the
context of a dynamic macromolecular machine known as the
spliceosome to carry out the excision of introns and ligation of
exons to form mature mRNAs [44]. With the goal of un-
derstanding SMA pathophysiology, here we have characterized
SMN complex activity and the consequence of its deficiency on
snRNP metabolism in the spinal cord of mouse models of the
disease.
We demonstrated that the levels of a subset of Gemin proteins
(namely Gemin2, Gemin6 and Gemin8) are significantly reduced
in the spinal cord of severe SMA mice compared with normal
mice, and that Gemin8 is an integral component of the SMN
Figure 6. Analysis of endogenous snRNP levels in the spinal cord of
severe SMA mice. Equal amounts of whole tissue extracts (200 mg)
from the spinal cord of normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/+;
mSmn
+/2) and severe SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day 3
were immunoprecipitated with anti-Sm (Y12) antibodies. Immunopre-
cipitated snRNAs were labeled at the 39-end with [
32P] pCp and
analyzed by electrophoresis on denaturing polyacrylamide gels and
autoradiography. Known snRNAs are indicated on the left. Note that the
intensity of signal is not proportional to the abundance of individual
snRNAs but reflects the efficiency with which they are labeled by T4
RNA ligase [52].
doi:10.1371/journal.pone.0000921.g006
Figure 7. Quantification of endogenous snRNP levels in tissues of
severe SMA mice. Immunoprecipitation experiments with anti-Sm (Y12)
antibodies from whole tissue extracts (200 mg) from either spinal cord,
brain or kidney extracts of normal (SMN2
+/+;mSmn
+/+), carrier (SMN2
+/
+;mSmn
+/2) and severe SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day
3 were carried out as in Figure 6. The relative amount of individual
snRNAs immunoprecipitated from each tissue was quantified using
a STORM 860 Phosphorimager (Molecular Dynamics) and expressed as
a percentage of that in normal mice, which is set arbitrarily as 100%.
The values from four independent experiments are presented as
mean6SEM (*p,0.05). Normal (black bars); carrier (dark grey bars);
severe SMA (light grey bars).
doi:10.1371/journal.pone.0000921.g007
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SMN (Figures 1 and S1). In contrast, the levels of Gemin4 and
unrip as well as those of several other SMN-interacting proteins
are unchanged. The SMN–dependent reduction of Gemin
proteins expression has also been observed in cultured cell lines
and likely results from degradation due to defective incorporation
into SMN complexes [27,29,31,45]. Importantly, the degree of
reduction in Gemin2, Gemin6 and Gemin8 expression in the
spinal cord of SMA mice correlates with disease severity
(Figure 4A), suggesting that these proteins might be involved in
the cellular activities of SMN whose impairment underlies SMA
pathology. In this regard, it is noteworthy that the beneficial effect
of treatment with trichostatin A on survival of SMND7 SMA mice
correlates with increased levels of functional SMN complexes in
the CNS [46]. Decreased levels of Gemin2, Gemin6 and Gemin8–
which are required for efficient snRNP assembly activity [27–31]–
may also exacerbate the consequence of reduced SMN expression
on Sm core formation in the spinal cord of SMA mice. Indeed, we
demonstrated that snRNP assembly activity is dramatically
reduced in spinal cord extracts from severe SMA mice (Figure 3).
A similar decrease in SMN levels and severe impairment of Sm
core formation are also observed in extracts from the other SMA
tissues analyzed here (Figures 2 and 3). Although quantitative
differences exist in the snRNP assembly activity of distinct normal
tissues and possibly also in the extent of its decrease in SMA
tissues, these results indicate that reduced capacity for Sm core
formation is a general biochemical deficiency in severe SMA mice.
Importantly, we showed that the degree of snRNP assembly
impairment in the spinal cord of SMA mice correlates with disease
severity (Figure 4B and 4C). Collectively, our findings provide
strong support to the possibility that deficiencies in snRNP
biogenesis contribute to SMA pathology.
For the first time, we demonstrated here that the impairment of
SMN function in Sm core formation leads to a significant decrease
in the levels of a subset of snRNPs in the spinal cord as well as
other tissues of severe SMA mice (Figures 6, 7 and 8). As indicated
also by similar levels of SmB protein in the spinal cord of normal,
carrier and SMA mice (Figure 1), the bulk of snRNPs is however
only marginally affected in SMA tissues. This is especially
remarkable considering the ten-fold decrease in snRNP assembly
activity in neural tissues from SMA mice. It is also in agreement
with the observation that steady-state snRNP levels are unchanged
in DT40 cells with severely reduced SMN levels and in Drosophila
larvae harboring SMN null mutations [32,36]. In light of the
striking discrepancy between the degree of reduction in snRNP
assembly and snRNP levels in tissues of SMA mice as well as other
model systems, it is important to consider that in vitro snRNP
assembly assays measure the capacity of Sm core formation in
extracts, which likely corresponds to the amount of SMN
complexes bound to Sm proteins and therefore capable of snRNP
assembly. However, reduced snRNP assembly capacity in vitro as
a consequence of low SMN levels may not necessarily translate
into a defect of snRNP synthesis in vivo if the SMN complexes are
in excess. In order for snRNP accumulation to be affected in vivo,
the SMN complex must fail to meet the demand for Sm core
formation on the snRNAs, which is dictated primarily by the rate
of snRNA transcription. Thus, the physiologically critical parameter
is the threshold of SMN activity required to support the level of
snRNP synthesis needed in vivo, which likely differs in distinct cells
and changes also with development. Only if SMN activity decreases
below this threshold insufficient snRNPs are made and steady-state
snRNP levels may be affected. Although it is generally assumed that
snRNP assembly is rate limiting in SMA, we found surprisingly that
snRNP synthesis in vivo is not affected in type I SMA fibroblasts
(Figure 5). Together with the overall modest reduction of snRNP
levels in SMA tissues, these results suggest that SMN complexes
competentforsnRNPassemblygreatlyexceedtheamountneededto
meet the in vivo demand for snRNP synthesis in most tissues and that
decreased SMN levels have little if any impact on snRNP
accumulation in SMA. An important implication is that, somewhat
similar to the situation in larval lethal Drosophila mutants [36], the
specific neuromuscular phenotype triggered by systemic SMN
deficiency in mouse models of SMA is not caused by global
depletion of spliceosomal snRNPs. Nevertheless, our finding that the
levels of a subset of snRNPs are significantly decreased in tissues of
severe SMA mice indicates that there are at least some cells in SMA
in which SMN capacity for snRNP assembly becomes overwhelmed
and insufficient snRNPs are made possibly due to a requirement for
high levels of snRNP synthesis.
One of the most strikingly unexpected findings of our study is
that impairment of SMN ubiquitous function specifically alters the
Figure 8. Analysis of endogenous U1 and U11 snRNA levels in the
spinal cord of severe SMA mice. (A) Northern blot analysis of four
increasing concentrations (0.5, 1, 2 and 4 mg) of total RNA from whole
spinal cord extracts of five normal (SMN2
+/+;mSmn
+/+) and five severe
SMA (SMN2
+/+;mSmn
2/2) mice at postnatal day 3 with probes specific
for the RNAs indicated on the left. (B) The intensity of signal of
individual RNAs at each concentration was quantified using a STORM
860 Phosphorimager (Molecular Dynamics) and values in the severe
SMA mice were expressed as a percentage of the corresponding ones in
normal mice, which are set arbitrarily as 100%. The values are presented
as mean6SEM. Normal (black bars); severe SMA (light grey bars).
doi:10.1371/journal.pone.0000921.g008
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of snRNPs and more prominently of U11. Spliceosomal snRNPs
are divided into two distinct classes depending on the type of
introns that they remove [47]. The vast majority of eukaryotic
introns are processed by the major (or U2-dependent) spliceosome
formed by U1, U2, U4/U6 and U5 snRNPs. Less than 1% of
introns are processed by the minor (or U12-dependent) spliceo-
some comprising U11, U12, U4atac/U6atac and U5 snRNPs.
Specific conserved sequence features distinguish the two types of
introns and determine their commitment to either the major or the
minor pre-mRNA splicing pathway [47,48]. Bioinformatic analysis
of intron sequences from the databases reveals the presence of
approximately seven hundred U12-type introns in the human
genome [49–51]. Consistent with the relatively low abundance of
the target introns, minor snRNAs (10
3–10
4 per cell) are two orders
of magnitude less abundant than major snRNAs (10
5–10
6 per cell)
[52]. Although the SMN complex assembles the Sm core on both
major and minor snRNAs [26,53], differences in the abundance,
efficiency of Sm core formation and turnover rate of individual
snRNAs might contribute to the observed effects of SMN
deficiency on the levels of specific snRNPs. Future studies will
be needed to address these issues directly. Regardless of the
mechanism(s), however, our results indicate that SMN deficiency
unevenly alters the physiological proportion of endogenous
snRNPs in tissues of severe SMA mice, and preferentially affects
the accumulation of U11 snRNP of the minor splicing pathway.
These findings have important potential implications for SMA
pathogenesis because the disease trigger targeted by SMN
reduction may lie within genes containing introns processed by
the minor splicing pathway. There is evidence that processing of
U12-type introns is slower and possibly more error prone than that
of U2-type introns under normal conditions and might represent
a rate-limiting step in the expression of genes that contain these
introns [50,54]. Decreased levels of minor snRNPs such as U11
may further enhance this situation and have deleterious con-
sequences on the expression of mRNAs containing U12-type
introns in cells of SMA patients. It is also conceivable that
although the minor splicing pathway processes a number of genes
only a few may be affected by SMN reduction because of
differences in the splicing efficiency of individual U12-type introns.
Dysfunctions in components of both constitutive and regulated
pre-mRNA splicing have been implicated in the disease mech-
anisms of an increasing number of human disorders [55,56]. In
addition, there is precedent for a model where reduction of
a particular splicing factor results in a tissue-specific phenotype.
Myotonic dystrophy is caused by nucleotide repeat expansions in
the non-coding region of specific mRNAs, which act to sequester
splicing factors such as the muscle blind protein away from the
pre-mRNA processing machinery leading to aberrant processing
of distinct target mRNAs in different tissues [57]. As a consequence
of this splicing deregulation, in mouse models of myotonic
dystrophy, the chloride channel 1 gene is processed incorrectly
during early postnatal development of skeletal muscle and the fetal
mRNA form that is not active in chloride conductance is retained
[58]. In turn, this affects the physiological increase in chloride
channel conductance in skeletal muscle resulting in myotonia and
muscle degeneration [59]. It is tantalizing to speculate that the
processing of one or more introns in specific genes that have
a critical role in motor neuron biology might be similarly affected
by reduced functionality of the U12-dependent spliceosome in
SMA. It is noteworthy that U12-dependent introns are not
randomly distributed in the genome but rather enriched in few
gene families [48–51]. Members of the voltage-gated ion channel
gene family contain an unusually high frequency of U12-
dependent introns and are especially interesting in the context of
SMA pathology [48]. These genes control numerous activities that
are critical for neuronal function and muscle contraction,
including action potential, signaling processes and synaptic
transmission, and whose deficiency is responsible for several
neuromuscular and neurological human disorders [60–62]. One
attractive albeit presently speculative scenario is that altered
processing of some members of this gene family could cause
electrophysiological disturbances that contribute to motor unit
dysfunction and SMA pathophysiology. It should be pointed out
however that there is no evidence of splicing defects in SMA and it
is not known whether the reduction of snRNP levels reported here
would indeed affect the functionality of the minor pre-mRNA
splicing pathway. Future studies will be needed to address the
many questions stemming from our work. In particular, whether
the minor splicing pathway rather than the major splicing pathway
is affected in SMA and whether defective processing of specific
mRNAs containing U12-dependent introns contributes to the
preferential vulnerability of motor neurons to reduced levels of
SMN.
MATERIALS AND METHODS
Animals and tissue harvesting
Severe SMA mice were produced from carrier parents of the
genotype SMN2
+/+;mSmn
+/2 (line 89; FVB.Cg-Tg(SMN2)89Ahmb
Smn1
tm1Msd) [16]. SMND7 SMA mice were generated from males
and females of the genotype SMN2
+/+;SmnD7
+/+;mSmn
+/2 (line
4299; FVB.Cg-Tg(SMN2*delta7)4299Ahmb Tg(SMN2)89Ahmb
Smn1
tm1Msd) [18]. SMN(A2G) SMA mice were bred from males
with the genotype SMN2
+/+;SMN(A2G)
+/+;mSmn
+/2 (line 2023;
FVB.Cg-Tg(SMN1*A2G)2023Ahmb Tg(SMN2)89Ahmb Smn1
tm1Msd)
and females with the genotype SMN2
+/+;mSmn
+/2 [19]. High
copy SMN2 SMA mice were produced by mating males of the
genotype SMN2(89)
+/+;SMN2(566)
+/+;mSmn
+/2 with females of
the genotype mSmn
+/2 [16]. All experiments were conducted in
accordance with the protocols described in the National Institutes
of Health Guide for the Care and Use of Animals and were approved by
the Ohio State University Institutional Laboratory Animal Care
and Use Committee. Mouse tissues were harvested from neonatal
pups at postnatal day 3 (with birth being defined as postnatal day
1). The pups were lightly anesthetized with isoflurane and were
then euthanized by rapid decapitation. Forebrains, spinal cords
and kidneys were rapidly dissected and immediately frozen in
liquid nitrogen. All tissue samples were stored at 280uC until use.
A tail biopsy, which was used for genotyping, was also taken from
each pup.
Genotyping
Neonatal offspring were genotyped using a PCR-based assay on
genomic DNA from tail biopsies—obtained after death—as
described previously [16–19,63]. The presence of the mSmn
knockout allele was determined by PCR amplification of NeoR/
mSmn junction site: NeoB, 59-gcagctgtgctcgacgttgtc-39 and
SmnInt2R, 59-taagaaagcctcgacgttgtc-39 (PCR conditions: 95uC
for 4 min, 35 cycles of 95uC for 1 min, 63uC for 1.5 min and 72uC
for 1 min followed by a final extension at 72uC for 4 min). PCR
primers designed to detect an intact mSmn allele were used to
distinguish SMA pups from carrier pups: mSmnEx2AF, 59-
ttttctccctcttcagagtgat-39 and mSmnEx2BR, 59-ctgtttcaagg-
gagttgtggc-39 (PCR conditions: 95uC for 4 min, 32 cycles of
95uC for 1 min, 57uC for 1 min and 72uC for 1 min followed by
a final extension at 72uC for 4 min). SMA mice (mSmn
2/2) would
be positive for the mSmn knockout PCR reaction and negative for
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+/2)
would be positive for both the mSmn knockout and intact mSmn
PCR reactions. Normal mice (mSmn
+/+) would test negative for the
mSmn knockout PCR but positive for the intact mSmn PCR
reaction. Both the SMN(A2G) and SMND7 transgenes were
identified by using the following PCR primers: SMNex4.5F, 59-
actgggaccaggaaagccaggt-39 and SMNex6R, 59-gccagtatgatagc-
cactcatg-39 (PCR conditions: 95uC for 4 min, 32 cycles of 95uC
for 1 min, 57uC for 1 min and 72uC for 1 min followed by a final
extension at 72uC for 4 min). The SMN2 transgene (both lines 89
and 566) was detected by the following PCR reaction: SMN2F2,
59-gcgatagagtgagactccatct-39 and SMN2R1, 59-gacatagaggtct-
gatctttagct-39 (PCR conditions: 95uC for 4 min, 32 cycles of
95uC for 1 min, 57uC for 1 min and 72uC for 1 min followed by
a final extension at 72uC for 4 min). To distinguish SMN2 (line 89)
from SMN2 (line 566), we performed the above PCR using
a limited number of 20 cycles and normalized band intensity to
that obtained from PCR-based detection of the endogenous,
single-copy gene, IL-2 (IL2-F, 59-ctaggccacagaattgaaagatct-39 and
IL2-R, 59-gtaggtggaaattctagcatcatcc-39) [64].
Antibodies
The antibodies used in this study were as follows: anti-SMN clone
8 (BD Transduction Laboratories), anti-Gemin2 2E17 [65], anti-
Gemin4 17D10 [66], anti-Gemin6 20H8 [28], anti-Gemin8 1F8
[27], anti-unrip 3G6 [27], anti-Sm Y12 (Lab Vision), anti-hnRNP
R/Qs 18E4 [67], anti-H1 and core histones (Chemicon), anti-
tubulin DM 1A (Sigma), anti-Profilin I and anti-Profilin II (kindly
provided by Dr. Witke).
Cell culture and treatments
Human fibroblast cell lines from one normal carrier individual
(GM03814) and four type I SMA patients (GM00232, GM09677,
GM03813, GM03815) were grown in RPMI 1640 medium
(BioWhittaker) containing 15% fetal bovine serum, 2 mM
glutamine and 1% penicillin/streptomycin. In pulse-labeling
experiments to monitor snRNP synthesis in vivo, subconfluent
human fibroblasts were incubated for 6 h with 100 mCi of [
32P]
phosphoric acid in medium without phosphate.
Extract preparation
Total protein extracts for Western blot analyses were prepared by
homogenization of frozen tissues in SDS/PAGE sample buffer
followed by brief sonication and boiling. Whole cell and tissue
extracts were prepared by homogenization of frozen tissues with
ice-cold reconstitution buffer (20 mM Hepes-KOH pH 7.9,
50 mM KCl, 5 mM MgCl2, 0.2 mM EDTA, 5% glycerol)
containing 0.01% NP40 as previously described [42]. Homo-
genates were then passed five times through a 25G needle and
centrifuged 15 min at 10,000 rpm at 4uC. Supernatants were
collected and protein concentration measured using the Lowry
method (Biorad). Extracts were then used directly for snRNP
assembly experiments or stored in frozen aliquots at 280uC for
Western blot and immunoprecipitation experiments. All protein
analyses were carried out by SDS/PAGE on 12% polyacrylamide
gels and Western blot.
In vitro assembly of snRNPs
U1 snRNA was transcribed in vitro from a linearized template
DNA in the presence of [a
32P] UTP (3000 Ci/mmol) and m7G
cap analogue (New England Biolabs), and then purified from
denaturing polyacrylamide gels according to standard procedures.
The snRNP assembly reactions were carried out for 1 h at 30uCi n
a volume of 20 ml of reconstitution buffer containing 0.01% NP40,
25 mg of whole tissue extracts, 10,000 cpm of in vitro transcribed
[a
32P] UTP-labeled U1 snRNA, 2.5 mM ATP and 10 mM E.coli
tRNA [26,42]. Reactions were then analyzed by immunoprecip-
itation with anti-Sm (Y12) antibodies or, following addition of
heparin and urea to a final concentration of 5 mg/ml and 2 M,
respectively, by electrophoresis on 6% polyacrylamide native gels
at 4uC and autoradiography.
Immunoprecipitation experiments
Immunoprecipitations with anti-Sm (Y12) antibodies from snRNP
assembly reactions or whole tissue extracts (200 mg) were carried out
in RSB-500 buffer (500 mM NaCl, 10 mM Tris-HCl pH 7.4,
2.5 mM MgCl2) containing 0.1% NP40, EDTA-free protease
inhibitor cocktail (Roche) and phosphatase inhibitors (50 mM
NaF, 0.2 mM Na3VO4)f o r2ha t4 uC. After five washes with the
same buffer, bound RNAs were recovered from immunoprecipitates
by proteinase K treatment, phenol/chloroform extraction and
ethanol precipitation. 39-end labeling experiments were carried out
in the presence of [
32P] pCp (3000Ci/mmol) and T4 RNA ligase
(Roche) following manufacturer’s instructions, and unincorporated
nucleotides were removed by centrifugation through micro Bio-Spin
P-30 columns (Biorad). RNAs were analyzed by electrophoresis on
6% polyacrylamide/8M urea gels and autoradiography. Immuno-
precipitated snRNAs were quantified using a STORM 860
Phosphorimager (Molecular Dynamics) and the ImageQuant
version 4.2 software. Two-tailed P values were calculated using the
unpaired Student t test and the InStat software.
Northern blot analysis
Total RNA from whole spinal cord extracts was analyzed by
electrophoresis on 6% polyacrylamide/8M urea gel or 1%
agarose-formaldehyde gel and transferred to a nylon membrane
(Genescreen Plus, Perkin Elmer). Antisense RNA probes corre-
sponding to mouse U1 (from nucleotide 122 to 157), mouse U11
(from nucleotide 58 to 82), mouse 28S ribosomal RNA (from
nucleotide 4400 to 4515) and mouse GAPDH mRNA (from
nucleotide 345 to 660) were transcribed in vitro in the presence of
[a
32P] UTP (3000 Ci/mmol) using the MEGAshortscript T7 kit
(Ambion). RNA probes (0,75610
6 cpm/ml) and sheared salmon
sperm DNA (200 mg/ml) were denatured at 100uC for 5 min and
then transferred to ice. Hybridization was carried out overnight at
50uC in hybridization buffer (1 M NaCl, 10% dextran sulphate,
50% formamide, 1% SDS).
SUPPORTING INFORMATION
Figure S1 SMN knockdown affects the levels of a subset of
Gemin proteins in HeLa cells. (A) HeLa S3 cells were transfected
with siRNAs against SMN, Gemin8 and luciferase (control) that
have been previously described [27–29]. 72 hours post-trans-
fection, equal amounts of total proteins were analyzed by Western
blot with antibodies against the proteins indicated on the left.
SMN knockdown in HeLa cells markedly affects the levels of
Gemin2, Gemin6, Gemin7 and Gemin8 but not of Gemin3,
Gemin4, Gemin5 and unrip. Note that Gemin2 decrease is not
observed upon Gemin8 knockdown and thus specific for SMN
reduction. (B) To quantify the decrease of Gemin proteins that are
affected by SMN knockdown, total proteins from HeLa cells in
which Gemin8 and SMN levels were reduced by RNA in-
terference as in (A) were analyzed together with the indicated serial
dilutions of total proteins from HeLa cells treated with siRNAs
against luciferase (control). Proteins were analyzed by Western blot
with antibodies against the proteins indicated on the left. For each
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western blot in the SMN RNAi sample and in serial dilutions of
the control RNAi sample indicates that SMN decrease most
prominently affects the levels of Gemin8 followed by Gemin2,
Gemin6 and Gemin7.
Found at: doi:10.1371/journal.pone.0000921.s001 (0.90 MB TIF)
Figure S2 In vitro snRNP assembly activity in kidney of severe
SMA mice. Equal amounts of whole tissue extracts (25 mg) from
the kidney of normal (SMN2+/+;mSmn+/+), carrier (SMN2+/+;
mSmn+/2) and severe SMA (SMN2+/+;mSmn2/2) mice at
postnatal day 3 were analyzed in snRNP assembly reactions with
radioactive U1 snRNA followed by immunoprecipitation with
anti-Sm (Y12) antibodies. Input (2.5%) and immunoprecipitated
U1 snRNAs were analyzed by electrophoresis on denaturing
polyacrylamide gels and autoradiography.
Found at: doi:10.1371/journal.pone.0000921.s002 (0.14 MB TIF)
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